Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen, Inspiration to establish European hemophilia commercial organization
The new commercial organization will be known as hemophilia business unit and will become a part of Ipsen’s existing commercial organization. As per the terms of the deal,
The new commercial organization will be known as hemophilia business unit and will become a part of Ipsen’s existing commercial organization. As per the terms of the deal,
Recently, the company has confirmed positive results from a Phase IIb trial evaluating Letermovir, an inhibitor of the human cytomegalovirus (HCMV). AiCuris CEO Helga Rubsamen-Schaeff said having obtained
With the help of I-Monitor solution, the sites will fill out the source worksheets and transmit them to PharmaVigilant. This could be accomplished via a scan, or can
The results from the study suggested that amphetamine-injected C57BL/6 mice showed a dose dependent reduction in hyperactivity when administered CM-182. Currently, the company is planning to conduct further
The ProMIS technology is a computer based algorithm that predicts disease specific epitopes (DSEs) in misfolded proteins based on thermodynamic analysis for identifying regions most likely to lose
Under collaboration with the Danish Novo Nordisk, Adimab will use its proprietary discovery platform for identifying fully human antibodies against two targets selected by Novo Nordisk. The tie
HMOs constitute a significant component of mother’s milk, and offer short and long-term benefits to infants from birth onwards. The tie up aims to enable the functional and
The delay was made in order to provide the FDA more time to review and respond to information and materials that have been provided by Gen-Prob in connection
As per the agreement Zymeworks has granted Merck, through a subsidiary, a worldwide license to develop and commercialize bi-specific antibodies toward certain exclusive therapeutic targets. Zymeworks will receive
The FDA recommended that additional retreatment data would be needed to assess the overall safety profile of ACZ885. Novartis submitted ACZ885 for regulatory review in the EU in